Abstract
Sulfasalazine and mesalazine (also known as mesalamine; 5-aminosalicylic acid) preparations have for many years been used for the treatment of IBD (i.e. ulcerative colitis and Crohn's disease), for both active disease and the control of remission. It has also been suggested that mesalazine is a chemoprophylactic agent that protects against the development of colorectal cancer. This Review focuses on the latest clinical evidence for the use of these aminosalicylates for the treatment of IBD, and concludes that sulfasalazine and mesalazine are useful for the treatment of both active and quiescent ulcerative colitis, whereas they have no clinical effect on either active or inactive Crohn's disease. Furthermore, evidence is lacking that mesalazine per se is a chemoprophylactic agent.
Key Points
-
There is robust evidence from randomized, controlled studies in favor of SASP or 5-ASA as a first-line therapy for the management of active mild to moderate ulcerative colitis and for maintaining remission
-
SASP is modestly effective for the treatment of active mild Crohn's disease; by contrast, 5-ASA is devoid of clinical effect on active Crohn's disease and on maintenance of medically and surgically induced remission
-
Given current knowledge, the many expert reviews and gastrointestinal society guidelines that support the role of SASP and 5-ASA in Crohn's disease need to be examined critically, with greatest reliance placed on high-quality individual studies and full acknowledgment of the limitations of meta-analyses
-
Evidence is lacking that 5-ASA per se is a chemoprophylactic agent, and it is therefore debatable whether maintained 5-ASA treatment in patients with IBD but without inflammation has the potential to reduce their risk of cancer development
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Svartz N (1988) Sulfasalazine: II. some notes on the discovery and development of salazopyrin. Am J Gastroenterol 83: 497–503
Svartz N (1942) Salazopyrin: a new sulfanilamide preparation. Acta Med Scand 110: 577–598
Das KM et al. (1973) Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289: 491–495
van Hees PAM (1979) Clinical and pharmacological aspects of sulfasalazine. Nijmegen: Gist-Brocades NV Delft
Peppercorn MA and Goldman P (1972) The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 181: 555–562
Azad Khan AK et al. (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892–895
Ireland A et al. (1990) Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin Sci (Lond) 78: 105–111
Klotz U (1985) Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 10: 285–302
Klotz U et al. (1980) Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 303: 1499–1502
Podolsky DK (2002) Inflammatory bowel disease. N Engl J Med 347: 417–429
Ahnfelt-Ronne I et al. (1990) Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98: 1162–1169
Nielsen OH et al. (1988) Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid. Aliment Pharmacol Ther 2: 203–211
Rousseaux C et al. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201: 1205–1215
Mahida YR et al. (1991) 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 32: 50–54
Kaiser GC et al. (1999) Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterology 116: 602–609
Stenson WF and Lobos E (1982) Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest 69: 494–497
Bus PJ et al. (1999) Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13: 1397–1402
Myers B et al. (1987) Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 28: 196–200
Nielsen OH and Bondesen S (1983) Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 16: 738–740
Dew MJ et al. (1982) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis: a controlled study [abstract]. Gut 23: A392
Cohen RD (2006) Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 24: 465–474
Frieri G et al. (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 13: 1413–1417
d'Albasio G et al. (1997) Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 92: 1143–1147
Nielsen OH (1982) Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol 17: 389–393
Hanauer SB et al. (2005) Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100: 2478–2485
Cohen RD et al. (2000) A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 95: 1263–1276
Ardizzone S and Porro GB (2002) Comparative tolerability of therapies for ulcerative colitis. Drug Saf 25: 561–582
Ransford RA and Langman MJ (2002) Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51: 536–539
Muller AF et al. (2005) Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 21: 1217–1224
van Staa TP et al. (2004) 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 126: 1733–1739
Esbjorner E et al. (1987) Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 76: 137–142
Mogadam M et al. (1981) Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80: 72–76
Moskovitz DN et al. (2004) The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99: 656–661
Marteau P et al. (1998) Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 12: 1101–1108
Ferrero S and Ragni N (2004) Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet 270: 79–85
Toovey S et al. (1981) Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 22: 445–451
Chermesh I and Eliakim R (2004) Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 36: 551–552
Goldman P and Peppercorn MA (1975) Drug therapy: sulfasalazine. N Engl J Med 293: 20–23
Juhl RP et al. (1976) Effect of sulfasalazine on digoxin bioavailability. Clin Pharmacol Ther 20: 387–394
Gilissen LP et al. (2005) The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 22: 605–611
Lowry PW et al. (2001) Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 49: 656–664
Spindel E (1983) Sulfasalazine and folate deficiency. JAMA 250: 900
Riley SA (1998) What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 42: 761–763
Watkinson G (1986) Sulphasalazine: a review of 40 years' experience. Drugs 32 (Suppl 1): 1–11
Travis S (2005) What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis? Nat Clin Pract Gastroenterol Hepatol 2: 564–565
Sutherland L et al. (2002) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane Database of Systematic Reviews, Issue 4, Art. No CD000544
Deventer SHJ et al. (2001) Prospective randomised open label blinded endpoint (PROBE) trial of high versus low dose mesalazine for prevention of relapse in patients with ulcerative colitis in remission [abstract]. Gastroenterology 120: A454
Paoluzi OA et al. (2005) Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 21: 1111–1119
Kruis W et al. (2003) The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1: 36–43
Marteau P et al. (2005) Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54: 960–965
Mawdsley JE and Rampton DS (2005) Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 54: 1481–1491
Kane S et al. (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114: 39–43
Kane SV (2006) Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 23: 577–585
Osterberg L and Blaschke T (2005) Adherence to medication. N Engl J Med 353: 487–497
Claxton AJ et al. (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23: 1296–1310
Lamet M et al. (2005) Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm Bowel Dis 11: 625–630
Robinson A et al. (2001) Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 358: 976–981
Kennedy AP et al. (2004) A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 53: 1639–1645
Truelove SC and Witts LJ (1955) Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2: 1041–1048
Xiao F and Sutherland LR (2002) Assessing disease activity and disease activity indices for inflammatory bowel disease. Curr Gastroenterol Rep 4: 490–496
Sands BE et al. (2005) Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis 11 (Suppl 1): S22–S28
Higgins PD et al. (2005) Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 100: 355–361
Baron JH et al. (1962) Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1: 1094–1096
Sutherland L and MacDonald JK (2006) Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD000543.pub2
Ardizzone S et al. (2006) Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55: 47–53
Marshall JK and Irvine EJ (2000) Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 95: 1628–1636
Hanauer S et al. (2000) Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 95: 1749–1754
Marteau P et al. (1998) Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 42: 195–199
Dew MJ et al. (1983) Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine. Lancet 2: 801
Donald IP and Wilkinson SP (1985) The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine. Postgrad Med J 61: 1047–1048
Campbell S and Ghosh S (2001) Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 13: 1297–1301
Summers RW et al. (1979) National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77: 847–869
Malchow H et al. (1984) European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86: 249–266
Singleton JW et al. (1993) Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 104: 1293–1301
Singleton J (1994) Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 107: 632–633
Hanauer SB and Stromberg U (2004) Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2: 379–388
Sandborn WJ and Feagan BG (2004) The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 127: 990–993
Akobeng AK and Gardener E (2005) Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. The Cochrane Database of Systematic Reviews, Issue 1, Art. No CD003715
Lochs H et al. (2000) Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 118: 264–273
Hanauer SB et al. (2004) Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723–729
Ardizzone S et al. (2004) Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730–740
Cottone M and Camma C (2000) Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 119: 597
Eaden JA et al. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526–535
Lashner BA (1991) Colon cancer surveillance in ulcerative colitis. Sem Gastroenterol 2: 126–131
Gillen CD et al. (1994) Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35: 1590–1592
Rutter M et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451–459
Munkholm P et al. (2006) Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion 73: 11–19
Winther KV et al. (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2: 1088–1095
Jess T et al. (2006) Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 130: 1039–1046
Rubio CA et al. (2001) Colorectal carcinoma in ulcerative colitis is decreasing in Scandinavian countries. Anticancer Res 21: 2921–2924
Rutter MD et al. (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130: 1030–1038
Velayos FS et al. (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345–1353
Mpofu C et al. (2004) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. The Cochrane Database of Systematic Reviews, Issue 2, Art. No CD000279
Acknowledgements
The preparation of this paper has been supported by grants from the Danish Research Agency and the Augustinus Foundation. The authors appreciate the skillful assistance of L Ferrero-Miliani in preparing the illustrations.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Nielsen, O., Munck, L. Drug Insight: aminosalicylates for the treatment of IBD. Nat Rev Gastroenterol Hepatol 4, 160–170 (2007). https://doi.org/10.1038/ncpgasthep0696
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0696
This article is cited by
-
ROS-responsive nanoparticles targeting inflamed colon for synergistic therapy of inflammatory bowel disease via barrier repair and anti-inflammation
Nano Research (2024)
-
Mucosal delivery of Lactococcus lactis carrying an anti-TNF scFv expression vector ameliorates experimental colitis in mice
BMC Biotechnology (2019)
-
5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity
The Journal of Antibiotics (2018)
-
5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects
Lung (2018)